Back to top
more

Lisata Therapeutics, Inc. (LSTA)

(Delayed Data from NSDQ)

$2.94 USD

2.94
4,549

+0.01 (0.36%)

Updated Aug 6, 2024 03:39 PM ET

After-Market: $3.00 +0.06 (2.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for LSTA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Lisata Therapeutics, Inc. [LSTA]

Reports for Purchase

Showing records 1 - 18 ( 18 total )

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

06/13/2024

Daily Note

Pages: 5

CENDIFOX Study Continues to Make Steady Progress; Pancreatic Cohort Completes Enrollment

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

05/21/2024

Company Report

Pages: 7

Positive European Pediatric Regulatory Agreement Brings Certepetide Closer to Market for Pancreatic Cancer

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

05/10/2024

Company Report

Pages: 7

1Q24 Results; Multiple Data Readouts Set Stage for Next Year; Topline Phase 2b ASCEND Data Expected 4Q24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

04/25/2024

Company Report

Pages: 7

Phase 2 Study of LSTA1 in mPDAC Begins Dosing Patients in China; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

03/01/2024

Company Report

Pages: 7

2023 Results; LSTA1 Momentum Builds Across Studies

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

01/17/2024

Daily Note

Pages: 5

First Patient Dosed in Phase 2a Study of LSTA1 in GBM; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

01/04/2024

Daily Note

Pages: 5

Early Signal Shows LSTA1 Potential For Complete Response in Advanced Gastroesophageal Tumor

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

12/13/2023

Company Report

Pages: 6

ASCEND Completes Enrollment Early; Cohort A Topline Data in 4Q24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

11/03/2023

Company Report

Pages: 6

3Q23 Results; Momentum Builds For LSTA1 As Clinical Progress Advances Across Programs

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

10/24/2023

Daily Note

Pages: 4

LSTA1 Phase 2 BOLSTER Study Doses First CCA Patient

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

09/14/2023

Company Report

Pages: 6

First Patient Treated in New Phase 2 Trial Aiming to BOLSTER SoC Efficacy in Combination With LSTA1 in Solid Tumors

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

08/15/2023

Company Report

Pages: 6

2Q23 Results; LSTA1 Builds Clinical Momentum; Data Readouts Anticipated Throughout 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

05/25/2023

Daily Note

Pages: 4

Enhancements to Phase 2B ASCEND Trial Set Stage for Pivotal Studies

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

05/10/2023

Company Report

Pages: 6

1Q23 Results; LSTA1 Development in Full Swing With Multiple Clinical Trials on the Horizon

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

04/18/2023

Company Report

Pages: 6

iLSTA Trial Achieves Lift Off and Finds a Welcome Partner in WARPNINE

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

03/31/2023

Company Report

Pages: 6

2022 Results; LSTA1 Clinical Studies Provide Multiple Shots on Goal; Further Trials Expected to Initiate in 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

11/11/2022

Company Report

Pages: 6

3Q22 Results; LSTA1 Is the Current Focus For Post- Merger Pipeline; Multiple Key Milestones Expected for 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Lisata Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

10/19/2022

Company Report

Pages: 13

It?s a Match; Merger Delivers Hybrid Portfolio With Meaningful Near-Term Catalysts; Price Target Adjusted to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party
// eof